CAH sees FY 2027 EPS growth guidance of 13%-15%
CAH reported strong FY 2026 results tied to specialty and generics growth and guided FY 2027 EPS growth of 13%-15%. The company cited acquisition integration, cost management and targeted M&A.
Strong FY 2026 results were driven by specialty and generics growth, with FY 2027 guidance projecting 13%-15% EPS growth. Integration of recent acquisitions, disciplined cost management, and targeted M&A are expected to support continued expansion across specialty, at-home and nuclear businesses. Based on Cardinal…